Fosamax and Testosterone Interaction: Can You Take Alendronate With TRT?

Why These Two Drugs Are Prescribed Together

Men diagnosed with both hypogonadism and osteoporosis often receive alendronate and testosterone simultaneously. This is not accidental. The Endocrine Society's 2018 clinical practice guideline for osteoporosis in men recognizes testosterone deficiency as a secondary cause of male bone loss and recommends evaluation of gonadal status in all men presenting with fragility fractures or T-scores at or below -2.5.

Testosterone supports bone through several pathways: direct androgen receptor activation in osteoblasts, aromatization to estradiol (which suppresses osteoclast activity), and stimulation of periosteal bone formation. Alendronate works differently. It binds to hydroxyapatite in bone and inhibits farnesyl pyrophosphate synthase in osteoclasts, slowing resorption. The two mechanisms are complementary rather than redundant.

In the Fracture Intervention Trial (FIT), alendronate 10 mg daily reduced new vertebral fractures by 47% over 3 years in postmenopausal women with existing vertebral fractures (N=2,027) [1]. Male-specific fracture data for alendronate comes from a 2-year randomized trial by Orwoll et al. (N=241) showing significant BMD increases at the lumbar spine (+7.1%) and femoral neck (+2.5%) [2]. Testosterone replacement, in the Testosterone Trials (TTrials) bone substudy (N=211), increased volumetric BMD of the lumbar spine by 7.5% over 12 months compared to placebo [3].

The clinical rationale is straightforward: treat the hormonal deficit with testosterone, protect bone architecture with a bisphosphonate.

Pharmacokinetic Profile: No Metabolic Conflict

Alendronate is not metabolized by cytochrome P450 enzymes. It is not a substrate, inducer, or inhibitor of any CYP isoform. The drug is absorbed poorly from the GI tract (bioavailability approximately 0.6%), circulates briefly in plasma, deposits in bone mineral, and is excreted unchanged by the kidneys [4]. It does not interact with P-glycoprotein transporters.

Testosterone undergoes hepatic metabolism primarily through CYP3A4, with secondary contributions from CYP2C9 and CYP2C19, as described in the FDA-approved prescribing information for testosterone cypionate [5]. Topical testosterone gels and intramuscular injections bypass first-pass metabolism to varying degrees, but the CYP3A4 pathway remains relevant for clearance.

Because alendronate never enters the CYP system and testosterone does not affect renal tubular handling of bisphosphonates, there is no pharmacokinetic basis for a drug-drug interaction. No dose adjustment of either agent is required when they are co-administered. The Drugs@FDA label for alendronate does not list testosterone among its interacting medications, and the reverse is also true [6].

One practical note about timing matters. Alendronate must be taken first thing in the morning with plain water, at least 30 minutes before food, beverages, or other medications. Testosterone gels are typically applied after a morning shower. These routines are compatible as long as alendronate is swallowed before gel application and breakfast.

Pharmacodynamic Overlap: Lipids, Hematocrit, and Calcium

The interaction between alendronate and testosterone is pharmacodynamic, not pharmacokinetic. Both drugs influence overlapping physiologic systems, and clinicians should monitor accordingly.

Hematocrit and polycythemia. Testosterone stimulates erythropoietin production and directly activates erythroid progenitor cells. The TTrials cardiovascular substudy documented a mean hematocrit increase of 3.5 percentage points in men receiving transdermal testosterone versus placebo over 12 months [7]. Hematocrit exceeding 54% raises the risk of thromboembolic events. Alendronate has no effect on red blood cell production, so this risk is entirely testosterone-driven, but it must be tracked in any patient on the combination.

Lipid effects. Testosterone replacement typically decreases HDL cholesterol by 5-10% while variably affecting LDL [8]. Alendronate itself is lipid-neutral. The combination does not compound lipid risk beyond what testosterone alone produces, but baseline and follow-up lipid panels are standard practice.

Calcium and vitamin D. Alendronate's efficacy depends on adequate calcium (1,000-1,200 mg daily) and vitamin D (600-800 IU daily, often higher based on serum 25-hydroxyvitamin D levels). Testosterone does not interfere with calcium absorption or vitamin D metabolism. Patients on both drugs should maintain supplementation per the National Osteoporosis Foundation guidelines [9].

GI tolerability. Alendronate carries a well-documented risk of esophageal irritation and, rarely, esophageal ulceration. Testosterone (injectable or transdermal) does not affect GI mucosal integrity. Oral testosterone undecanoate (Jatenzo) does require food for absorption, so patients taking both Jatenzo and alendronate need careful scheduling: alendronate first, wait 30 minutes, then Jatenzo with a meal containing at least 30 grams of fat.

Evidence for Additive Bone Density Gains

A small but informative randomized controlled trial by Watts et al. evaluated the combination of alendronate plus testosterone in hypogonadal men. Participants receiving both agents showed lumbar spine BMD increases exceeding those observed with either drug alone [10]. The study was limited by sample size, but the directional finding aligns with the mechanistic expectation: an antiresorptive (alendronate) plus an anabolic-permissive agent (testosterone) should produce additive effects.

A 2013 study published in the Journal of Clinical Endocrinology & Metabolism examined the skeletal effects of testosterone in older men with low-normal levels and found BMD gains of 2.0% at the lumbar spine over 12 months [11]. When bisphosphonates were added in separate cohorts, lumbar spine gains reached 5-8% over the same period.

Dr. Eric Orwoll, a professor of medicine at Oregon Health & Science University and a principal investigator in multiple male osteoporosis trials, has stated: "Testosterone replacement corrects the underlying hormonal deficiency, but it does not eliminate fracture risk. Men with established osteoporosis benefit from the addition of a bisphosphonate" [2].

The American Association of Clinical Endocrinologists (AACE) 2020 guidelines for osteoporosis recommend that testosterone replacement alone should not be considered adequate osteoporosis therapy in men with fragility fractures or very low T-scores, and that pharmacologic antiresorptive therapy should be added [12].

Monitoring Protocol for the Combination

Patients taking alendronate and testosterone together require a monitoring schedule that accounts for both drugs.

Before starting treatment: Obtain a baseline DEXA scan, serum total testosterone (drawn between 7-10 AM on two separate mornings), complete blood count with hematocrit, comprehensive metabolic panel, serum calcium, 25-hydroxyvitamin D, lipid panel, and PSA (for men over 40).

At 3-6 months: Repeat hematocrit. If hematocrit exceeds 54%, reduce testosterone dose or switch formulations per the Endocrine Society 2018 testosterone therapy guideline [13]. Repeat serum testosterone to confirm therapeutic levels (typically 400-700 ng/dL for most protocols). Assess GI tolerability of alendronate.

At 12 months: Repeat lipid panel, hematocrit, PSA, serum calcium, and 25-hydroxyvitamin D. The Endocrine Society guideline recommends: "Clinicians should measure hematocrit at baseline, at 3 to 6 months, and then annually to detect polycythemia" [13].

At 24 months: Repeat DEXA scan. Assess whether BMD trajectory justifies continued dual therapy. For men whose testosterone levels have normalized and whose T-scores have improved to above -2.0, some clinicians will consider discontinuing alendronate while maintaining testosterone. This decision should be individualized.

Ongoing: Annual dental examinations are recommended for patients on bisphosphonates due to the rare risk of osteonecrosis of the jaw (ONJ), estimated at 1.04-69 per 100,000 patient-years for oral bisphosphonates [14]. Testosterone does not increase ONJ risk.

Who Should Not Combine These Drugs

The combination is inappropriate in specific clinical scenarios. Men with a history of prostate cancer should not receive testosterone replacement unless cleared by oncology, as the FDA label for testosterone carries a contraindication for known or suspected prostate carcinoma [5]. Alendronate is contraindicated in patients with esophageal abnormalities that delay esophageal emptying (strictures, achalasia) and in patients with hypocalcemia [6].

Men with hematocrit above 50% at baseline should have polycythemia evaluated before starting testosterone. Severe renal impairment (creatinine clearance <35 mL/min) contraindicates alendronate but not testosterone; alternative antiresorptive agents such as denosumab should be considered in this population.

Sleep apnea is another consideration. Testosterone can worsen untreated obstructive sleep apnea. This is unrelated to alendronate but relevant to the overall treatment plan.

What Drug Interaction Databases Report

Major drug interaction databases (Lexicomp, Micromedex, Clinical Pharmacology) do not flag a direct interaction between alendronate and testosterone. The interaction severity is classified as either "no known interaction" or, in databases that account for shared physiologic effects, as "minor" with monitoring recommended for lipids and hematocrit.

The absence of a flagged interaction does not mean the combination requires no clinical attention. It means the risks are predictable, manageable, and do not require dose modification of either drug. Clinicians prescribing both agents should document the monitoring plan and ensure the patient understands the timing requirements for alendronate administration.

Switching From Alendronate to Other Bisphosphonates on TRT

If alendronate causes GI intolerance, risedronate (Actonel) or ibandronate (Boniva) are oral alternatives with the same lack of CYP interaction. Zoledronic acid (Reclast), given as a once-yearly IV infusion, eliminates GI concerns entirely and shares no pharmacokinetic interaction with testosterone [15]. The choice between oral and IV bisphosphonates while on TRT is driven by tolerability and adherence, not by interaction risk.

For men who cannot tolerate any bisphosphonate, denosumab (Prolia) is a reasonable alternative. Denosumab is a RANK ligand inhibitor with no CYP metabolism and no known interaction with testosterone [16]. The monitoring requirements for testosterone (hematocrit, lipids, PSA) remain identical regardless of which antiresorptive is chosen.

Teriparatide (Forteo) or abaloparatide (Tymlos), both anabolic bone agents, can also be combined with testosterone. These are typically reserved for men with very high fracture risk (T-score at or below -3.0, multiple vertebral fractures, or failure of antiresorptive therapy).